– In Ongoing Phase 1/2 Study, Single Subcutaneous Doses of ALN-CC5 Achieve Potent, Statistically Significant, and Highly Durable C5 Knockdown of up to 96% – – After Single Dose, ALN-CC5 Also Achieves ...

HYANNIS -- In recognition of Military Family Month, Cape Cod 5 (CC5) on Friday announced a $25,000 donation to Cape and Islands Veterans Outreach Center to help fund its new Veterans Home in Dennis, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and collaborators today presented initial results from Part C of its ongoing ...

Alnylam Pharmaceuticals, Inc. ALNY announced initial positive results from an ongoing phase I/II study on ALN-CC5. ALN-CC5 is an investigational RNA interference (RNAi) therapeutic targeting ...

SAN JOSE, Calif., Aug. 28, 2025 /PRNewswire/ -- Reallusion officially releases Character Creator 5 (CC5), a major upgrade that brings the character creation ecosystem into the HD era. Its powerful ...

Alnylam Pharmaceuticals, Inc. has announced new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting ...

Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...

What is the current share price of Clever Culture Systems Limited (CC5)? Clever Culture Systems Limited's (CC5) current share price is $0.02. This constitutes a price movement of 0% when compared to ...

An announcement from LBT Innovations Limited ( ($AU:CC5) ) is now available. Clever Culture Systems Ltd has issued 2,500,000 fully paid ordinary ...

CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced initial positive results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an ...